Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis

Table 3

Results of univariate and multivariate linear regression analyses (155 patients with psoriasis type I versus 36 cases with psoriasis type II). SNPs with in the univariate analysis were included in the multivariate analysis. Only polymorphisms that were significant in the multivariate analysis are shown.

SNP	Gene	Model	Risk genotype	Univariate Ps patients type I versus type II		Multivariate
				OR (95% CI)	value	OR (95% CI)	value
rs1801274	FCGR2A	A	CC/CT	1.96 (1.12–3.45)	0.016	5.26 (1.11–25)	0.037
rs191190	TNFR1	D	CC/CT	0.43 (0.17–1.11)	0.065	0.01 (1.44E − 04–0.44)	0.018
rs763361	CD226	D	TT/CT	2.08 (0.99–4.35)	0.056	33.33 (1.11–1000)	0.043
rs12459358	PSORS6	A	TT/CT	2.44 (1.32–4.55)	0.002	11.11 (1.32–100)	0.026
rs10499194	TNFAIP3	D	TT/CT	0.38 (0.17–0.90)	0.02	0.01 (6.77E − 05–0.61)	0.030
rs12191877	HLA-C	A	TT/CT	2.33 (1.23–4.35)	0.006	12.50 (1.06–100)	0.045
rs6920220	TNFAIP3	A	AA/AG	0.55 (0.30–1.03)	0.068	0.05 (0.003–0.90)	0.042
rs361525	TNF-α	C	AG	2.17 (0.62–7.69)	0.087	0.01 (5.48E − 05–0.50)	0.024
rs1576	CCHCR1	D	GG/GC	2.56 (1.22–5.26)	0.012	166.67 (2.32–1000)	0.019

FCGR2A: Fc fragment of IgG low affinity IIa receptor; TNFR1: tumor necrosis factor receptor 1; CD226: CD226 antigen; PSORS6: psoriasis susceptibility 6; TNFAIP3: tumor necrosis factor alpha-induced protein 3; HLA-C: major histocompatibility complex; TNFAIP3: tumor necrosis factor alpha-induced protein 3; TNF-α: tumor necrosis factor alpha; CCHCR1: coiled-coil alpha-helical rod protein 1; SNPs: single-nucleotide polymorphisms; OR: odds ratio of presenting type I psoriasis; CI: confidence interval; A: additive; D: dominant; C: codominant.